Medically refractory neurosarcoidosis treated with infliximab

Internal Medicine Journal

Volumn 41, Issue 4, 2011, Pages 354-357

  Pereira, J ^a   Anderson, N E ^b   Mcauley, D ^b   Bergin, P ^b   Kilfoyle, D ^b   Fink, J ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Anti inflammatory agent; Factor alpha; Infliximab; Monoclonal antibody; Sarcoidosis; Tumour necrosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN DISEASE; CASE REPORT; DRUG DOSE REDUCTION; GRANULOMATOUS INFLAMMATION; HEADACHE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PARALYSIS; PARAPLEGIA; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; SARCOIDOSIS; SPINAL CORD DISEASE; URINE RETENTION; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SARCOIDOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954986581     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02457.x     Document Type: Article

References (16)

1. Moller DR, Chen ES. What causes sarcoidosis? Curr Opin Pulm Med 2002; 8: 429-34.
2. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009; 80: 297-304.
3. Judson MA. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am J Med Sci 2008; 335: 26-33.
4. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF etal. Central nervous system sarcoidosis - diagnosis and management. QJM 1999; 92: 103-17.
5. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolatemofetil. Neurology 2009; 72: 337-40.
6. Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103: 268-73.
7. Santos ES, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry 2010; 81: 241-6.
8. Kobylecki C, Shaunak S. Refractory neurosarcoidosis responsive to infliximab. Pract Neurol 2007; 7: 112-5.
9. Dolhun R, Sriram S. Neurosarcoidosis presenting as longitudinally extensive transverse myelitis. J Clin Neurosci 2009; 16: 595-7.
10. Toth C, Martin L, Morrish W, Coutts S, Parney I. Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. Acta Neurol Scand 2007; 116: 259-62.
11. Kumar G, Kang CA, Giannini C. Neurosarcoidosis presenting as a cerebellar mass. J Gen Intern Med 2007; 22: 1373-6.
12. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006; 41: 766-8.
13. Sollberger M, Fluri F, Baumann T, Sonnet S, Tamm M, Steck AJ etal. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004; 251: 760-1.
14. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004; 117: 277-9.
15. Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003; 60: 426-30.
16. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59: 1660-1.